CCP RCT

  • Research type

    Research Study

  • Full title

    TESTING THE EFFICACY OF THE CANNABIS CLINIC FOR PSYCHOSIS (CCP) INTERVENTION FOR CANNABIS USE REDUCTION/CESSATION IN FIRST EPISODE PSYCHOSIS PATIENTS WITH CANNABIS USE DISORDERS (CUD)

  • IRAS ID

    361577

  • Contact name

    Marta Di Forti

  • Contact email

    marta.diforti@kcl.ac.uk

  • Sponsor organisation

    King’s College London

  • Duration of Study in the UK

    2 years, 11 months, 30 days

  • Research summary

    People suffering from psychosis who use cannabis experience more relapses, long and compulsory admissions, with huge costs to the individual, families and health services. The Cannabis Clinic for Psychosis (CCP) was developed to respond to this clinical need. A published review of the CCP's intervention showed its safety and efficacy in supporting people suffering from psychosis with reducing their cannabis use. Nevertheless, for the CCP model of care to be applied widely and benefit a larger clinical population, its intervention needs to be tested in a Randomised Control Trial (RCT). The proposed CCP RCT is a waiting list randomised controlled trial that aims to evaluate the clinical efficacy of the existing CCP intervention. Participants will be adults currently under the care of South London and Maudsley (SLaM) Early Intervention Teams for first onset psychosis, who are dependent on cannabis and who express an intention to reduce or stop their use. The RCT primary outcome will measure changes in all participants' cannabis use. Participants will be randomised to either the intervention group or the waiting list control group receiving Treatment As Usual (TAU). The CCP intervention comprises 12 weekly (+/- 4 weeks) one-to-one sessions, with optional participation in a weekly online peer group. Sessions are delivered by trained clinicians and include evidence-based psychosocial techniques, including Motivational Interviewing (MI), Cognitive Behavioural Therapy (CBT), and support for co-occurring tobacco use. The treatment is non-pharmacological and administered via participant-led approach that accommodates online or face-to-face sessions to meet the patient preference. Qualitative data from the recent CCP proof of concept paper indicate that the flexibility in allowing patients choice on the session’s modality (online/face to face, hybrid) increased and maintained engagement.
    The study is fully funded by the Maudsley Charity and due to last 30 months from the start of recruitment.

  • REC name

    London - Camberwell St Giles Research Ethics Committee

  • REC reference

    25/LO/0877

  • Date of REC Opinion

    13 Jan 2026

  • REC opinion

    Further Information Favourable Opinion